Stock Ticker

  • Loading stock data...

The Preclinical Influenza Nanoparticle Study By Novavax, Inc (NASDAQ:NVAX) Published In Vaccine

The stock of Novavax, Inc (NASDAQ:NVAX) closed at $1.06 maintaining the same standing in yesterday’s trading session. This provider has today made an announcement regarding the publication of data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in the journal Vaccine. It is directing a lot of effort towards the development of the NanoFlu which is expected to help guard the older adults by protecting them from seasonal influenza.

NanoFlu was clearly described by a manuscript based on the 2017-2018 World Health Organization (WHO) influenza strains recommendations. This research led to the discovery that NanoFlu induced microneutralizing (MN) and hemagglutination-inhibition (HAI) antibodies against a wide array of the influenza subtypes.

NanoFlu was found to elicit higher MN and HAI antibody responses exceeding the ones induced by the high-dose vaccine against recent (homologous) A(H1N1) by 26-fold, A(H3N2) by 7-fold and the B strain viruses by 2-fold.

Gregory Glenn opined “These data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults, Sanofi`s Fluzone® High-Dose.”

The data emanating from the study revealed that NanoFlu sparked about improved responses to both the drifted strains and the influenza strains.

Novavax has for over a decade engaged in the development of both the seasonal and pandemic influenza vaccine candidates. It takes pride in its superior attributes of the nanoparticle based vaccine candidates. It has also done much in the direction of transitioning its influenza development activities to its nanoparticle vaccine platform.

The publication’s data validated the provider’s nanoparticle vaccine platform and also went ahead to give a pretty strong rationale for a total overhaul and advancement of NanoFlu into the Phase 1/2 clinical trial.

The provider’s objective will be to do all within its means to see to it that it is able to deliver superior, differentiated vaccine to the a commercial market with the capacity to generate about $3 billion. Challenges have been there along the way but the company has handled them well.

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https://plus.google.com/100770875710593766367/posts

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts